Unknown

Dataset Information

0

Clinical Service Delivery of Noninvasive Prenatal Diagnosis by Relative Haplotype Dosage for Single-Gene Disorders.

ABSTRACT: A relative haplotype dosage (RHDO)-based method was developed and implemented into routine clinical practice for noninvasive prenatal diagnosis (NIPD) of multiple single-gene disorders: spinal muscular atrophy, Duchenne and Becker muscular dystrophies, and cystic fibrosis. This article describes the experiences of the first 152 pregnancies to have NIPD by RHDO as part of a routine clinical service. Provision of results within a clinically useful time frame (mean, 11 calendar days) was shown to be possible, with a very low failure rate (4%), none being due to a technical failure. Where follow-up confirmatory testing was performed for audit purposes, 100% concordance was seen with the NIPD result, and no discrepancies have been reported. The robust performance of the assay, together with high sensitivity and specificity, demonstrates that NIPD by RHDO is feasible for use in a clinical setting.

SUBMITTER: Young E 

PROVIDER: S-EPMC7471768 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Clinical Service Delivery of Noninvasive Prenatal Diagnosis by Relative Haplotype Dosage for Single-Gene Disorders.

Young Elizabeth E   Bowns Benjamin B   Gerrish Amy A   Parks Michael M   Court Samantha S   Clokie Samuel S   Mashayamombe-Wolfgarten Chipo C   Hewitt Julie J   Williams Denise D   Cole Trevor T   Allen Stephanie S  

The Journal of molecular diagnostics : JMD 20200615 9

A relative haplotype dosage (RHDO)-based method was developed and implemented into routine clinical practice for noninvasive prenatal diagnosis (NIPD) of multiple single-gene disorders: spinal muscular atrophy, Duchenne and Becker muscular dystrophies, and cystic fibrosis. This article describes the experiences of the first 152 pregnancies to have NIPD by RHDO as part of a routine clinical service. Provision of results within a clinically useful time frame (mean, 11 calendar days) was shown to b  ...[more]

Similar Datasets

Unknown Noninvasive prenatal diagnosis of β-thalassemia by relative haplotype dosage without analyzing proband.
| S-EPMC6825866 | biostudies-other
Unknown Non-invasive prenatal diagnosis of single gene disorders with enhanced relative haplotype dosage analysis for diagnostic implementation.
| S-EPMC10124834 | biostudies-literature
Unknown Non-invasive prenatal diagnosis of spinal muscular atrophy by relative haplotype dosage.
| S-EPMC5386415 | biostudies-literature
Unknown Non-invasive prenatal diagnosis of Duchenne and Becker muscular dystrophies by relative haplotype dosage.
| S-EPMC4864947 | biostudies-literature
Unknown Bayesian-based noninvasive prenatal diagnosis of single-gene disorders.
| S-EPMC6396420 | biostudies-literature
Unknown Noninvasive prenatal testing for β-thalassemia by targeted nanopore sequencing combined with relative haplotype dosage (RHDO): a feasibility study.
| S-EPMC7952549 | biostudies-literature
Unknown Noninvasive prenatal diagnosis of duchenne muscular dystrophy in five Chinese families based on relative mutation dosage approach.
| S-EPMC8607717 | biostudies-literature
Genomics Bayesian-based noninvasive prenatal diagnosis of single-gene disorders
| PRJNA484073 | ENA
Genomics Bayesian-based noninvasive prenatal diagnosis of single-gene disorders
| PRJNA484074 | ENA
Unknown Noninvasive prenatal diagnosis of monogenic disorders based on direct haplotype phasing through targeted linked-read sequencing.
| S-EPMC8502361 | biostudies-literature